Publications by authors named "Howard Ozer"

Claim this Profile
A
A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200 mg/m and total marrow irradiation (TMI) in patients with relapsed/refractory multiple myeloma.
Pritesh Patel, Annie L Oh, Matthew Koshy, Karen Sweiss, Santosh L Saraf, Howard Ozer

Leuk Lymphoma· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MicroRNAs in glioblastoma pathogenesis and therapy: A comprehensive review.
Bhavesh K Ahir, Howard Ozer, Herbert H Engelhard, Sajani S Lakka

Crit Rev Oncol Hematol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid and Sensitive Detection of Breast Cancer Cells in Patient Blood with Nuclease-Activated Probe Technology.
Sven Kruspe, David D Dickey, Kevin T Urak, Giselle N Blanco, Matthew J Miller, Howard Ozer

Mol Ther Nucleic Acids· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A validated, transitional and translational porcine model of hepatocellular carcinoma.
Kyle M Schachtschneider, Regina M Schwind, Kwame A Darfour-Oduro, Arun K De, Lauretta A Rund, Howard Ozer

Oncotarget· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Î
β-Catenin Is a Candidate Therapeutic Target for Myeloid Neoplasms with del(5q).
Liping Li, Yue Sheng, Wenshu Li, Chao Hu, Nupur Mittal, Howard Ozer

Cancer Res· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Oncopig Cancer Model: An Innovative Large Animal Translational Oncology Platform.
Kyle M Schachtschneider, Regina M Schwind, Jordan Newson, Nickolas Kinachtchouk, Mark Rizko, Howard Ozer

Front Oncol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Symptomatic Massive Splenomegaly in Persistent Polyclonal B-cell Lymphocytosis Requiring Splenectomy.
Shanel B Bhagwandin, Elliot S Weisenberg, Howard Ozer, Ajay V Maker

Open J Clin Med Case Rep· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erlotinib is not effective in patients with JAK2V617F-positive polycythemia vera.
Mohamad Cherry, Mohamad Khawandanah, Zhizhuang Joe Zhao, Samer Srour, Howard Ozer

Ann Hematol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Costs of care for lung and colon cancer patients receiving chemotherapy following FDA policy changes.
Kevin T Stroupe, Elizabeth Tarlov, Thomas W Weichle, Qiuying L Zhang, Laura C Michaelis, Howard Ozer

Support Care Cancer· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
miR-let-7f-1 regulates SPARC mediated cisplatin resistance in medulloblastoma cells.
Padmavathi Pannuru, Ranadheer Dontula, Anwar A Khan, Englehard Herbert, Howard Ozer

Cell Signal· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative FRET imaging to visualize the invasiveness of live breast cancer cells.
Shaoying Lu, Yi Wang, He Huang, Yijia Pan, Eric J Chaney, Howard Ozer

PLoS One· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MicroRNA 203 Modulates Glioma Cell Migration via Robo1/ERK/MMP-9 Signaling.
Ranadheer Dontula, Ashok Dinasarapu, Chandramu Chetty, Padmavathi Pannuru, Engelhard Herbert, Howard Ozer

Genes Cancer· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hemoglobin levels triggering erythropoiesis-stimulating agent therapy in patients with cancer: the shift after United States Food and Drug Administration policy changes.
Kevin T Stroupe, Elizabeth Tarlov, Todd A Lee, Thomas W Weichle, Qiuying L Zhang, Howard Ozer

Pharmacotherapy· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trends in anemia management in lung and colon cancer patients in the US Department of Veterans Affairs, 2002-2008.
Elizabeth Tarlov, Kevin T Stroupe, Todd A Lee, Thomas W Weichle, Qiuying L Zhang, Howard Ozer

Support Care Cancer· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A case of acute myeloid leukemia initially treated as chronic lymphocytic leukemia: what do we know about t(4;12)(q12;p13)?
Aref Al-Kali, Mohamad Cherry, Kristopher Kimmell, Jennifer Holter, William Kern, Howard Ozer

Cancer Genet Cytogenet· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer.
Prithviraj Bose, Howard Ozer

Expert Opin Investig Drugs· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AIDS-related plasmablastic lymphoma with dramatic, early response to bortezomib.
Prithviraj Bose, Christopher Thompson, Darshan Gandhi, Bassam Ghabach, Howard Ozer

Eur J Haematol· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study.
Wolfram E Samlowski, James Moon, J Philip Kuebler, Craig R Nichols, David R Gandara, Howard Ozer

Cancer Invest· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
Mehdi Hamadani, Lubna Chaudhary, Farrukh T Awan, Jawad K Khan, Kiarash Kojouri, Howard Ozer

J Oncol Pharm Pract· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low incidence of neutropenic events in patients with lymphoma receiving first-cycle pegfilgrastim with chemotherapy: results from a prospective community-based study.
Stephen J Noga, Janak K Choksi, Beiying Ding, Lyndah Dreiling, Howard Ozer

Clin Lymphoma Myeloma· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use.
Howard Ozer, Barry Mirtsching, Michael Rader, Susan Luedke, Stephen J Noga

Oncologist· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of combination chemotherapy, docetaxel and epirubicin as neoadjuvant therapy for women with breast cancer.
Arafat Tfayli, Jennifer Holter, Abby Bova, Siddhartha Venkatappa, Susie Bullock, Howard Ozer

Anticancer Res· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-Cycle CSF use in breast cancer and NHL: guidelines and recommendations.
Aref Al-Kali, Howard Ozer

Oncology (Williston Park)· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The timing of chemotherapy-induced neutropenia and its clinical and economic impact.
Howard Ozer

Oncology (Williston Park)· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia.
Jeffrey Crawford, John A Glaspy, Ronald G Stoller, Dianne K Tomita, Martha E Vincent, Howard Ozer

Support Cancer Ther· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis